Background
This clinical trial assessed the efficacy and safety of Camrelizumab plus Rivoceranib in patients with advanced liver cancer.
Camrelizumab is anti-PD-1 immunotherapy drug given intravenous.
Rivoceranib, also known as Apatinib, is a VEGFR tyrosine kinase inhibitor given orally.
All patients in this clinical trial received the combination. It was a multicenter, phase 2 study which enrolled patients with advanced liver cancer who were treatment-naive or refractory/intolerant to first-line targeted therapy.
Results
70 patients in the first-line setting and 120 patients in the second-line setting were enrolled.
As of January 10, 2020,
- 34.3% of patients in the first line experienced their cancer either stopped from continuous growth or decrease in size of lesions
- 22.5% of patients in the second-line experienced their cancer either stopped from continuous growth or decrease in size of lesions
- Median time until the disease has progressed under the treatment was 5.7 months in the first line patients
- Median time until the disease has progressed under the treatment was 5.5 months in the second line patients
- At 12 months 74.7% of the first line patients were alive
- At 12 months 68.2% of the first line patients were alive
Side Effects
The most common side effect was hypertension which occurred in 34.2% of patients.
Conclusion
- Camrelizumab combined with Rivoceranib showed promising efficacy and manageable safety in patients with advanced liver cancer in both the first-line and second-line setting.
- It might represent a novel treatment option for these patients.
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
About Liver Cancer
Liver cancer, also called “Hepatocellular carcinoma”, HCC, has several types based on the type of cells which turn cancerous.
Liver cancer is aggressive, since most of the patients are diagnosed in an advanced stage, where the disease is considered incurable, for the most part.
The patient’s life expectancy is poor and currently stands on 3-5 year; this is with the support of the standard treatments.
To improve patients’ chances, the American Society for Clinical Oncology, ASCO, that includes various specialists in its panel, such as oncologists, radiologists, gastrologists among others, guides oncologists to inform liver cancer patients in all topics related to clinical trials in every stage of their disease.
The National Cancer Institute, NCI, of the United States, stresses that for liver cancer patients, the preferred treatment option is to join one of the many clinical trials around the world and thus increase the chances of success over the standard protocols.
